Moderna shares sink after leaked cancer data missed expectations

Moderna's stock prices took a dive after leaked data from a melanoma vaccine trial showed a 58% reduction in the risk of recurrence or death, but investors were left underwhelmed as the results didn't surpass the high expectations set by Wall Street. This outcome highlights the pressure biopharmaceutical companies face to meet aggressive market forecasts, even when promising results are achieved in clinical trials. The incident underscores the importance of balancing realistic expectations with scientific progress in the fast-paced world of vaccine development.